Premature ovarian insufficiency in patients with systemic lupus erythematosus on cyclophosphamide: a systematic review and meta-analysis - Summary - MDSpire

Premature ovarian insufficiency in patients with systemic lupus erythematosus on cyclophosphamide: a systematic review and meta-analysis

  • By

  • Manuel Ramón García-Sáenz

  • Claudia Ramírez-Rentería

  • Etual Espinosa-Cárdenas

  • Ernesto Sosa-Eroza

  • José Luis Eduardo Doval-Caballero

  • Paulo César Gete Palacios

  • Fabiola Pazos-Pérez

  • Mario César Ocampo-Torres

  • Rocío Catana-Hernández

  • Miguel Ángel Vázquez-Zaragoza

  • Adolfo Camargo-Coronel

  • Juan Rodrigo Gómez-Bernal

  • Aldo Ferreira-Hermosillo

  • May 28, 2026

  • 0 min

Share

Objective:

To estimate the prevalence of premature ovarian insufficiency (POI) in women with systemic lupus erythematosus (SLE) exposed to cyclophosphamide (CYC) and explore sources of heterogeneity.

Key Findings:
  • The pooled prevalence of POI in SLE treated with CYC was 15% (95% CI 7-26%).
  • Substantial heterogeneity was observed (I2 = 85%; Cochran’s Q = 73.98, p <0.0001).
  • Prevalence decreased in studies published after 2005 (9%) compared to pre-2005 (29%).
  • Age at exposure was identified as a significant predictor of POI prevalence.
Interpretation:

The findings indicate a substantial burden of POI among women with SLE treated with CYC.

Limitations:
  • Variability in diagnostic criteria for POI across studies may affect prevalence estimates.
  • Cumulative CYC dose was not independently associated with prevalence, possibly due to lower-dose regimens adopted after 2005.
Conclusion:

Women with SLE treated with CYC have an estimated prevalence of POI of approximately 15%.

Original Source(s)

Premature ovarian insufficiency in patients with systemic lupus erythematosus on cyclophosphamide: a systematic review and meta-analysis

  • by Manuel Ramón García-Sáenz, Claudia Ramírez-Rentería, Etual Espinosa-Cárdenas, Ernesto Sosa-Eroza, José Luis Eduardo Doval-Caballero, Paulo César Gete Palacios, Fabiola Pazos-Pérez, Mario César Ocampo-Torres, Rocío Catana-Hernández, Miguel Ángel Vázquez-Zaragoza, Adolfo Camargo-Coronel, Juan Rodrigo Gómez-Bernal, Aldo Ferreira-Hermosillo

  • May 28, 2026

Related Content

From algorithm to verification: based on network toxicology and machine learning, the immunomodulatory role of IGFBP1/MKI67/C9 in perfluorooctanoic acid-induced osteoarthritis was discovered, and a diagnostic model was constructed

Development of an improved preclinical humanized mouse platform representing the diverse clinical phenotypes of Sjögren’s syndrome

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.